RevolutionLogo.png
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
03 mai 2021 07h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
Immunicum AB present
Immunicum AB presenterar prekliniska data från studier med Ilixadencel och DCP-001 vid det 18:e årsmötet för cancerimmunoterapi (CIMT)
03 mai 2021 02h00 HE | Immunicum AB
Pressrelease 3 maj 2021 Immunicum AB presenterar prekliniska data från studier med Ilixadencel och DCP-001 vid det 18:e årsmötet för cancerimmunoterapi (CIMT) ...
Immunicum AB Present
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
03 mai 2021 02h00 HE | Immunicum AB
Press Release 03 May 2021 Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting Immunicum AB (publ;...
Logo.png
Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies
29 avr. 2021 20h30 HE | DelveInsight Business Research LLP
Los Angeles, USA, April 29, 2021 (GLOBE NEWSWIRE) -- Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies  A comprehensive analysis of...
AB Science today ann
AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
29 avr. 2021 13h05 HE | AB Science
                                                                                                                                                                                                       ...
AB Science annonce a
AB Science annonce aujourd'hui que l'étude de phase 2B/3 (AB12003) du masitinib dans le cancer de la prostate métastatique hormono-résistant (mCRPC) a atteint son critère d'évaluation principal prédéfi
29 avr. 2021 13h05 HE | AB Science
                                                                                                                                                                                             COMMUNIQUE...
Coherus BioSciences, Inc. logo
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
29 avr. 2021 07h30 HE | Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit
28 avr. 2021 16h05 HE | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Cytovia.png
Stanley R. Frankel, MD, FACP joins Cytovia Therapeutics as Chief Medical Officer
28 avr. 2021 13h16 HE | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 28, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Novel late-stage col
Novel late-stage colorectal cancer treatment proves effective in preclinical models
28 avr. 2021 09h29 HE | University of Minnesota Medical School
MINNEAPOLIS/ST.PAUL, April 28, 2021 (GLOBE NEWSWIRE) -- In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage...